Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Miami Herold Mon, Sep. 26, 2005, Singer a voice for breast-cancer victims by Jerry Berrio.
References
Schwartz LM, Woloshin S, Fowler FJ, Jr., Welch HG. Enthusiasm for cancer screening in the United States. JAMA. Jan 7 2004;291(1):71–78.
Aronowitz RA. Do not delay: breast cancer and time, 1900–1970. Milbank Q. 2001; 79(3):355–386, III.
Eddy DM. The frequency of cervical cancer screening. Comparison of a mathematical model with empirical data. Cancer. Sep 1 1987;60(5):1117–1122.
Harris P, Carnes M. Is there an age at which we should stop performing screening pap smears and mammography? Cleve Clin J Med. Apr 2002;69(4):272–273.
Parnes BL, Smith PC, Conry CM, Domke H. When should we stop mammography screening for breast cancer in elderly women? J Fam Pract. Feb 2001;50(2):110–111.
Shapiro S, Coleman EA, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. Oct 1998;27(5):735–742.
Kaplan RM. Shared medical decision making. A new tool for preventive medicine. Am J Prev Med. Jan 2004;26(1):81–83.
Arnold K. Mammography guidelines in the national spotlight again. J Natl Cancer Inst. Mar 20 2002;94(6):411–413.
Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. The U.S. Preventive Services Task Force. Am J Prev Med. Jul–Aug 1994;10(4):187–193.
Levenson D. Routine prostate screening may be unnecessary and harmful. Rep Med Guidel Outcomes Res. Jan 10 2003;14(1):5–7.
Weston R, Parr N. New NHS guidelines for PSA testing in primary care. Lancet. Jan 4 2003;361(9351):89–90.
Farhat WA, Habbal AA, Khauli RB. A guideline to clinical utility of prostate specific antigen. Saudi Med J. Mar 2000;21(3):223–227.
New PSA guidelines for older men. Johns Hopkins Med Lett Health After 50. Sep 1998;10(7):1–2.
Duperray B, Junrod B. Depistage du cancer du sein. Medecine. 2006;2:364–367.
American Cancer Society. California Division, California Cancer Registry. California cancer facts & figures. Oakland, CA: American Cancer Society California Division 2008.
Welch HG. Should I Be Tested for Cancer? Berkeley, CA: Universlty of California Press; 2004.
Black WC, Welch HG. Screening for disease. AJR Am J Roentgenol. Jan 1997;168(1): 3–11.
Welch HG, Black WC. Evaluating randomized trials of screening. J Gen Intern Med. Feb 1997;12(2):118–124.
Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. Apr 29 1993;328(17):1237–1243.
Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health. Jun 1989;43(2):107–114.
Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ. Oct 15 1988;297(6654): 943–948.
Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer. Dec 1 1997;80(11):2091–2099.
Roberts MM, Alexander FE, Anderson TJ, et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. Feb 3 1990;335(8684):241–246.
Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40–49 years. Cmaj. Nov 15 1992;147(10):1459–1476.
Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst. Sep 20 2000;92(18):1490–1499.
Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. Mar 3 1999;91(5):434–437.
Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. Nov 30 1996;348(9040): 1472–1477.
Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. Nov 30 1996; 348(9040):1467–1471.
Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer. Jan 15 1990;45(1): 26–33.
Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. Aug 16 2000;92(16): 1308–1316.
Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. Feb 6 2002;94(3):167–173.
de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol. Aug 2003;14(8):1185–1189.
Barry MJ. Early detection and aggressive treatment of prostate cancer: groping in the dark. [Comment On: J Gen Intern Med. 2000 Oct;15(10):739–48]. J Gen Int Med. 2000;15(10):749–751.
Barry MJ. PSA screening for prostate cancer: the current controversy–a viewpoint. Patient Outcomes Research Team for Prostatic Diseases [see comments]. Ann Oncol. 1998;9(12):1279–1282.
U.S. Preventive Services Task Force, United States. Office of Disease Prevention and Health Promotion. Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2nd ed. Washington, DC: U.S. Dept. of Health and Human Services Office of Public Health and Science Office of Disease Prevention and Health Promotion: Supt. of Docs. U.S. G.P.O. distributor; 1996.
Screening for prostate cancer. American College of Physicians [see comments]. Ann Intern Med. 1997;126(6):480–484.
Physicians. AAoF. Summary of policy redommendations for periodic health examinations. www.aafp.org.exam/pos_gen_guide.html. 2000.
Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology. 2000;14(2):267–272, 277–268, 280 passim.
Society AC. Prostate Cancer: Treatment Guidelines for Patients Version II. Atlanta: American Cancer Society; 2001.
McLellan F. Independent US panel fans debate on mammography. Lancet. Feb 2 2002;359(9304):409.
Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF. Mammographic screening: no reliable supporting evidence? Lancet. Feb 2 2002; 359(9304):404–405.
Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. Mar 16 2002;359(9310):909–919.
Gelmon KA, Olivotto I. The mammography screening debate: time to move on. Lancet. Mar 16 2002;359(9310):904–905.
Navarro AM, Kaplan RM. Mammography screening: prospects and opportunity costs. Womens Health. Winter 1996;2(4):209–233.
Barton MB, Moore S, Polk S, Shtatland E, Elmore JG, Fletcher SW. Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits. J Gen Intern Med. Mar 2001;16(3):150–156.
Fletcher SW. Whither scientific deliberation in health policy recommendations? Alice in the Wonderland of breast-cancer screening. N Engl J Med. Apr 17 1997;336(16): 1180–1183.
Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. Oct 20 2001;358(9290):1340–1342.
Barratt A, Howard K, Irwig L, Salkeld G, Houssami N. Model of outcomes of screening mammography: information to support informed choices. BMJ. Apr 23 2005;330 (7497):936.
Baines CJ. Mammography screening: are women really giving informed consent? J Natl Cancer Inst. Oct 15 2003;95(20):1508–1511.
Zahl PH, Maehlen J. Model of outcomes of screening mammography: spontaneous regression of breast cancer may not be uncommon. BMJ. Aug 6 2005;331(7512):350; author reply 351.
Zahl P, Mæhlen J, Welch H. The Natural History of Invasive Breast Cancers Detected by Screening Mammography. Arch Intern Med. Nov 24 2008.
Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer. Mar 2005;41(4):508–515.
Gates TJ. Screening for cancer: evaluating the evidence. Am. Family Physician, 2001; 63(3):513–522.
Andersen LD, Remington PL, Trentham-Dietz A, Robert S. Community trends in the early detection of breast cancer in Wisconsin, 1980–1998. Am J Prev Med. Jan 2004;26(1): 51–55.
Wennberg JE. The Dartmouth Atlas of Health Care in the United States. Hanover, NH: Trustees of Dartmouth College; 1998.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kaplan, R.M. (2009). Screening for Cancer. In: Disease, Diagnoses, and Dollars. Springer, New York, NY. https://doi.org/10.1007/978-0-387-74045-4_5
Download citation
DOI: https://doi.org/10.1007/978-0-387-74045-4_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-74044-7
Online ISBN: 978-0-387-74045-4
eBook Packages: MedicineMedicine (R0)